EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope

Satoshi Miyamoto, Hiddo J L Heerspink, Dick de Zeeuw, Kota Sakamoto, Michihiro Yoshida, Masao Toyoda, Daisuke Suzuki, Takashi Hatanaka, Tohru Nakamura, Shinji Kamei, Satoshi Murao, Kazuyuki Hida und 16 weitere

Kidney International · 2024-11 · 106 (5) · 972-984

DOI: 10.1016/j.kint.2024.08.019 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2024-11. Verfasst von Satoshi Miyamoto und 27 weiteren Autor:innen. Beteiligte Einrichtung: Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan; Department of Internal Medicine, Innoshima General Hospital, On…. Hauptthemen laut MEDLINE: Canagliflozin, Glomerular Filtration Rate, Albuminuria, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitsubishi Tanabe Pharma Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinGlomerular Filtration RateAlbuminuriaDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicDiabetic NephropathiesDisease ProgressionHumansMaleFemaleMiddle AgedAgedTreatment OutcomeCreatinine

Stichwörter der Autor:innen

CANPIONE studycanagliflozinchronic kidney disease microalbuminuriapreintervention eGFR slopesodium-glucose cotransporter 2 inhibitor

Substanzen

CanagliflozinSodium-Glucose Transporter 2 InhibitorsCreatinine

Autor:innen und Institutionen

  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan; Department of Internal Medicine, Innoshima General Hospital, Onomichi, Japan. Electronic address: s1miyamoto@okayama-u.ac.jp.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: h.j.lambers.heerspink@umcg.nl.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
  • Suzuki Diadetes Clinic, Atsugi, Japan.

Förderung

  • Mitsubishi Tanabe Pharma Corporation

Zitieren

APA

Miyamoto, S., Heerspink, H. J. L., de Zeeuw, D., Sakamoto, K., Yoshida, M., Toyoda, M., Suzuki, D., Hatanaka, T., Nakamura, T., Kamei, S., Murao, S., Hida, K., Ando, S., Akai, H., Takahashi, Y., Kitada, M., Sugano, H., Nunoue, T., Nakamura, A., …, & CANPIONE study Investigators (2024). A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney International. https://doi.org/10.1016/j.kint.2024.08.019

Vancouver

Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, et al. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney International. 2024. doi:10.1016/j.kint.2024.08.019

BibTeX
@article{Miyamoto2024,
  author = {Miyamoto, Satoshi and Heerspink, Hiddo J L and de Zeeuw, Dick and Sakamoto, Kota and Yoshida, Michihiro and Toyoda, Masao and Suzuki, Daisuke and Hatanaka, Takashi and Nakamura, Tohru and Kamei, Shinji and Murao, Satoshi and Hida, Kazuyuki and Ando, Shinichiro and Akai, Hiroaki and Takahashi, Yasushi and Kitada, Munehiro and Sugano, Hisashi and Nunoue, Tomokazu and Nakamura, Akihiko and Sasaki, Motofumi and Nakatou, Tatsuaki and Fujimoto, Kei and Kawanami, Daiji and Wada, Takashi and Miyatake, Nobuyuki and Kuramoto, Hiromi and Shikata, Kenichi and CANPIONE study Investigators, CANPIONE study Investigators},
  title = {A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope},
  journal = {Kidney International},
  year = {2024},
  doi = {10.1016/j.kint.2024.08.019}
}
Kostenlos starten →